Dr. Ramaswamy Govindan, MD of Washington University Medical School gives an update on ALK+ lung cancer agents at ASCO 2016
Browsing: Acute Lymphoblastic Leukemia
Dr. Fadi Braiteh, MD of Comprehensive Cancer Centers of Nevada notes that autoimmune can be delayed in immunotherapy
Dr. Nathan Pennell, MD of Cleveland Clinic describes the safety and efficacy differences between PD-1 and PD-L1 inhibitors
Dr. Alexander Spira, MD of Virginia Cancer Specialists discusses the durable response of atezolizumab
Anna Schuh, MD, PhD, from the University of Oxford, discusses the importance of genomic analysis in chronic lymphocytic leukemia (CLL)…
Gail Roboz, MD from Weill Medical College of Cornell University, New York, NY discusses the availability of commercially available genetic…
George Follows, MA, BM, BCh, PhD, FRCP, FRCPath from Cambridge University Hospitals, Cambridge, UK gives an overview of the session…
Anas Younes, MD from the Memorial Sloan Kettering Cancer Center, New York, NY discusses the cost of new drugs in…
Dr. Heather Wakelee, MD of Stanford School of Medicine outlines the best way to test newly diagnosed NSCLC in the…
Petros Grivas, MD discusses anti PD-1 versus anti PD-L1 in urothelial carcinoma
test
Dr. Omid Hamid, MD of The Angeles Clinic presents updated results of KEYNOTE-001 006 and 029 for advanced melanoma
Robert Dreicer, MD of the University of Virginia answers the question why urothelial cancer for checkpoint inhibitor therapeutics
Dr. Fadi Braiteh, MD of Comprehensive Cancer Centers discusses the POPLAR results show statistic significant improvement in overall survival
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy discusses the research activities of the European Research…
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy discusses the side effects of novel drugs in…
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy discusses drug combinations for the treatment of chronic…
Kostas Stamatopoulos, MD, PhD from CERTH Institute of Applied Biosciences, Thessaloniki, Greece gives an overview of the European Research Initiative…
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy talks about venetoclax for chronic lymphocytic leukemia (CLL).…
Noopur Raje, MD from the Massachusetts General Hospital, Boston, MA gives an overview of the Phase III POLLUX trial on…
Kostas Stamatopoulos, MD, PhD from CERTH Institute of Applied Biosciences, Thessaloniki, Greece discusses the issues associated with the rapid development…
Gareth Morgan, MD, FRCP, FRCPath, PhD from the UAMS Myeloma Institute, Little Rock, AR discusses the use of FISH in…
Andrew Spencer, MD, PhD from the Monash University, Melbourne, Australia discusses the side effects of panobinostat in multiple myeloma (MM).…
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy talks about the stratification of chronic lymphocytic leukemia…
Philippe Moreau, MD from the University Hospital of Nantes, Nantes, France gives an overview of his session on how monoclonal…
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy discusses minimal residual disease (MRD) negativity in chronic…
Noopur Raje, MD from the Massachusetts General Hospital, Boston, MA gives an overview of the Phase Ib/II study of ricolinostat…
Kostas Stamatopoulos, MD, PhD from CERTH Institute of Applied Biosciences, Thessaloniki, Greece discusses the progress of research in chronic lymphocytic…
Gareth Morgan, MD, FRCP, FRCPath, PhD from the UAMS Myeloma Institute, Little Rock, AR provides an overview of his talk…
Anna Schuh, MD, PhD, from the University of Oxford, UK, gives an overview of her talk on the advances in…
Francesco Forconi, MD, PhD from the University of Southampton, Southampton, UK gives an overview of his talk on the structure…
Andrew Spencer, MD, PhD from the Monash University, Melbourne, Australia provides an overview of his talk on epigenetics and HDAC…
As part of our coverage from the 2016 American Society of Clinical Oncology annual meeting, MPN experts Dr. Srdan Verstovsek,…
As part of our coverage from the 2016 American Society of Clinical Oncology annual meeting, MPN experts Dr. Srdan Verstovsek,…
Expert Dr. Russell Szmulewitz of the University of Chicago Medical Center describes the endocrinology of prostate cancer and provides an…
Evan Yu, MD of Seattle Cancer Care Alliance goes over next steps after FDA approval for Atezelozimab
Even though there is a tremendous access to new drug therapies, doctors have yet to determine the best way to…
Discussed are the new IMWG Criteria in MRD testing in multiple myeloma, which is to be published in Lancet Oncology.…
Heather Wakelee, MD of Stanford Medicine discusses genetic heterogeneity and genomic alterations in KRAS mutated NSCLC
The doctors consider mSMART classification to look at high-, intermediate-, and standard-risk myeloma. They discuss, with the increasing depth of…
The third question of the series is Are you proactive regarding your patients possible comorbidities? In particular, the doctors consider…
The first question of the series is What is the impact of the new diagnostic criteria? The criteria to which…
Alexander Spira, MD of Virginia Cancer Specialists discusses PD-L1 expression in tumor and immune cells in the microenvironment from the…
Nathan Pennell, MD of Cleveland Clinic talks about the future of genotypical NSCLC immunotherapy
Dr. Omid Hamid, MD of The Angeles Clinic outlines the evidence that uveal melanoma is responsive to immunotherapy
Dr Arjun V. Balar, MD of NYU Langone Medical Center discusses how upper tract disease did better in IMVigor210 trial
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg…
An expert panel, led by Dr. Tomasz Beer, explores research discussed at the 2016 American Society of Clinical Oncology (ASCO)…
Is there hope for lung cancer patients with genetic alterations who have become resistant to therapies? On location at ASCO…
Does knowing your molecular mutation in earlier stage lung cancer have any significance in selecting a treatment modality? Is there…